Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38
Pre-publication versions of this article are available by contacting firstname.lastname@example.org.
|20 Sep 2016||Submitted||Original manuscript|
|17 Mar 2017||Reviewed||Reviewer Report - Joan Lewis-Wambi|
|8 May 2017||Reviewed||Reviewer Report - Hamidreza Montazeri Aliabadi|
|9 May 2017||Reviewed||Reviewer Report - Andreja Ambriovic-Ristov|
|29 Jun 2017||Author responded||Author comments - Katharina Gohr|
|Resubmission - Version 2|
|29 Jun 2017||Submitted||Manuscript version 2|
|10 Aug 2017||Reviewed||Reviewer Report - Andreja Ambriovic-Ristov|
|26 Sep 2017||Author responded||Author comments - Katharina Gohr|
|Resubmission - Version 3|
|26 Sep 2017||Submitted||Manuscript version 3|
|19 Oct 2017||Editorially accepted|
|3 Nov 2017||Article published||10.1186/s12885-017-3695-5|
How does Open Peer Review work?
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting email@example.com.
You can find further information about the peer review system here.